Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart J Pocock

Showing results (191-200 of 349) with videos related to

Pageof 35
Sort By:
Journal of the American College of Cardiology|September 24, 2021
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced TrialJames L Januzzi, Faiez Zannad, Stefan D Anker, et al.
JACC. Heart Failure|October 25, 2024
Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved TrialWolfram Doehner, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure|November 15, 2023
Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR programJoão Pedro Ferreira, Milton Packer, Javed Butler, et al.
International Journal of Cardiology|March 8, 2017
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational studyShaun G Goodman, Jose C Nicolau, Gema Requena, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 2, 2015
Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trialsJennifer Yu, Roxana Mehran, Tim Clayton, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 17, 2018
Two-year outcomes of high bleeding risk patients with acute coronary syndrome after Biolimus A9 polymer-free drug-coated stents: a LEADERS FREE substudyChristoph J Jensen, Christoph K Naber, Philip Urban, et al.
The American Journal of Cardiology|December 28, 2014
Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarctionJosephine Warren, Roxana Mehran, Jennifer Yu, et al.
European Journal of Heart Failure|March 18, 2017
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trialArnaud Olivier, Bertram Pitt, Nicolas Girerd, et al.
The New England Journal of Medicine|June 11, 2004
A factorial trial of six interventions for the prevention of postoperative nausea and vomitingChristian C Apfel, Kari Korttila, Mona Abdalla, et al.
Journal of the American College of Cardiology|June 11, 2025
Re-Evaluating Recurrent Events in Heart Failure Trials: Patterns, Prognostic Implications, and Analytical ImprovementsAudinga-Dea Hazewinkel, John Gregson, Stuart J Pocock, et al.
Pageof 35

Showing results (191-200 of 349) with videos related to

Sort By:
Pageof 35
Journal of the American College of Cardiology|September 24, 2021
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced TrialJames L Januzzi, Faiez Zannad, Stefan D Anker, et al.
JACC. Heart Failure|October 25, 2024
Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved TrialWolfram Doehner, Stefan D Anker, Javed Butler, et al.
European Journal of Heart Failure|November 15, 2023
Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR programJoão Pedro Ferreira, Milton Packer, Javed Butler, et al.
International Journal of Cardiology|March 8, 2017
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational studyShaun G Goodman, Jose C Nicolau, Gema Requena, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 2, 2015
Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trialsJennifer Yu, Roxana Mehran, Tim Clayton, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|January 17, 2018
Two-year outcomes of high bleeding risk patients with acute coronary syndrome after Biolimus A9 polymer-free drug-coated stents: a LEADERS FREE substudyChristoph J Jensen, Christoph K Naber, Philip Urban, et al.
The American Journal of Cardiology|December 28, 2014
Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarctionJosephine Warren, Roxana Mehran, Jennifer Yu, et al.
European Journal of Heart Failure|March 18, 2017
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trialArnaud Olivier, Bertram Pitt, Nicolas Girerd, et al.
The New England Journal of Medicine|June 11, 2004
A factorial trial of six interventions for the prevention of postoperative nausea and vomitingChristian C Apfel, Kari Korttila, Mona Abdalla, et al.
Journal of the American College of Cardiology|June 11, 2025
Re-Evaluating Recurrent Events in Heart Failure Trials: Patterns, Prognostic Implications, and Analytical ImprovementsAudinga-Dea Hazewinkel, John Gregson, Stuart J Pocock, et al.
Pageof 35